

CERTIFICATE OF ANALYSIS

Product Name	Eloralintide (LY-3841136), Cat.#: 319888 (TFA removed)
Lot No.	MTFB21065-260805
Sequence	{γ-Glu}-Cys*-Asn-Thr-Ala-Thr-Cys*-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{α-Me-Phe}-Leu-Val-Arg-Ser-Ser-Asn-{N-Me-Asn}-Phe-Gly-Pro-{Lys(diacid-C20-γ-Glu-γ-Glu)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH ₂
Dissolution condition	100%H ₂ O
Modification	sodium salt, Methylene bridge: Cys2-Cys7
Molecular Weight (MW)	4526.10
Storage	-20°C

Test Items	Specifications	Results
MW by MS	4526.00	Conforms
Purity by HPLC	>98%	98.548%
Peptide content	N/A	N/A
N content	N/A	N/A
TFA content	N/A	N/A
Endotoxin content	N/A	N/A
Appearance	White to off-white lyophilized powder	Conforms
Quantity	1100.0mg	20.0mg*50 + 5.0mg*20

NovoPro Bioscience Inc. (hereafter NovoPro) warrants material of said quality at the time of sale. It is the sole responsibility of the customers to determine the adequacy of all materials for any intended or specific purpose or use. NovoPro's sole obligation is to replace the material up to the extent of the purchase price. This warranty applies only to products in original packaging and does not apply to a product which has been tampered with or altered in any way in or which has been misused or damaged by accident or negligence. All claims must be received writing (by fax or email) within 30 days from date when product arrive at the destination city and failure to do so shall constitute a waiver by customers for any and all such claims.

Certified by: 
 Quality Assurance Department

Sep/16/2026




Sample Information

Order ID :MTFB21065
 Name :Eloralintide (LY-3841136)
 Sequence :{ γ -Glu}-Cys*-Asn-Thr-Ala-Thr-Cys*-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-
 { α -Me-Phe}-Leu-Val-Arg-Ser-Ser-Asn-{N-Me-Asn}-Phe-Gly-Pro-
 {Lys(diacid-C20- γ -Glu- γ -Glu)}-Leu-Pro-Pro-Thr-Glu-Val-Gly
 -Ser-Asn- Thr-Tyr-NH2
 Lot. No :MTFB21065-260805
 Pump A :0.1%Trifluoroacetic in 100% water
 Pump B :0.1%Trifluoroacetic in 100% acetonitrile
 Total Flow :1ml/min
 Wavelength :214nm
 Analytical column type :Kromasil 100-5-C18 (4.6*250mm*5 μ m)
 Dissolution method :100%H2O
 Inj. Volume : 30ul

Time	Module	Action	Value
0.01	Pumps	B.Conc	35
30.00	Pumps	B.Conc	65
33.00	Pumps	B.Conc	100
38.00	Pumps	B.Conc	100
40.00	Pumps	B.Conc	35
50.00	Controller	Stop	


Chromatogram



Peak Table

Detector A 214nm

Peak#	Ret. Time	Area	Height	Area%
1	16.946	175343	24361	0.748
2	17.166	23109817	1519090	98.548
3	17.629	165072	17181	0.704
Total		23450232	1560632	100.000



Sample Information

Dissolution method	:15%ACN+85%H2O	Interface	:ESI	Prerod Bias	:+4.5kv
Date Acquired	:2026/09/14 16:04:22	Nebulizing Gas Flow	:1.50L/min	Detector	:-0.2kv
Injection Volume	:0.2ul	CDL Temp	:250°C	T.Flow	:0.2ml/min
Block Temp	:200	CDL Volt	:0v	B.conc	:50%H2O/50%MEOH

Order ID :MTFB21065

Name :Eloralintide (LY-3841136)

Sequence :{γ-Glu}-Cys*-Asn-Thr-Ala-Thr-Cys*-Ala-Thr-Gly-{Orn}- Leu- Ala-Glu-
 {α-Me-Phe}-Leu-Val-Arg-Ser-Ser-Asn-{N-Me-Asn}-Phe-Gly-Pro-
 {Lys(diacid-C20-γ-Glu-γ-Glu)}-Leu-Pro-Pro-Thr-Glu-Val-Gly
 -Ser-Asn- Thr-Tyr-NH2

Lot. No :MTFB21065-260805

Theoretical :4526.10

Observed :4526.00

Instructions for dissolving Eloralintide (LY-3841136)

The Eloralintide is soluble in pure water, 1 x PBS, or Bacteriostatic (BAC) water.

The suggested concentration is 5.0 mg/ml.

The steps are as below:

1. Adding 1.0 ml ultrapure water to the 2.0 ml tube of Eloralintide.
2. Wait about 1 minute at room temperature until the solution is clear, which indicates the peptide is fully dissolved;
3. Use a sterile 0.22 μ m membrane filter for a particle-free and bacteria-free solution.
For example, Catalog# SLGPR33RB, Millipore Millex-GP Syringe Filter Unit, 0.22 μ m, polyethersulfone, 33 mm, gamma sterilized.

References of Eloralintide

1. Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271.
doi:10.1016/j.molmet.2025.102271
<https://pubmed.ncbi.nlm.nih.gov/41109426/>
2. Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes Obes Metab. 2026;28(4):2651-2660.
doi:10.1111/dom.70439
<https://pubmed.ncbi.nlm.nih.gov/41559929/>